Axogen director sells 14,150 shares under 10b5-1 plan

Q: What insider transaction did Axogen, Inc. (AXGN) report in this Form 4?

Axogen, Inc. reported that director Kathy Johnson Weiler sold 14,150 shares of common stock on August 7, 2026. The transaction was classified as a sale in an open market or private transaction and left her with 0 directly held shares afterward.

Q: At what prices were the Axogen (AXGN) shares sold by Kathy Johnson Weiler?

The reported weighted average sale price was $45.298 per share. According to the disclosure, the 14,150 shares were sold in multiple trades at prices ranging from $44.43 to $46.47 per share, with detailed trade breakdowns available on request.

Q: How many Axogen (AXGN) shares does Kathy Johnson Weiler hold after this reported sale?

After the reported sale of 14,150 shares, the Form 4 lists 0 shares of Axogen common stock held directly by Kathy Johnson Weiler. The report does not list any additional derivative positions or indirect holdings in this particular filing.

Q: What role does the reporting person in this Axogen (AXGN) Form 4 hold at the company?

The reporting person, Kathy Johnson Weiler, is identified in the disclosure as a director of Axogen, Inc. She is not listed as an officer or 10% owner in this filing, which focuses on her reported common stock sale transaction.

Axogen, Inc. director Kathy Johnson Weiler reported selling 14,150 shares of common stock on August 7, 2026 in a sale classified as an open market or private transaction.

Filing Impact

(High)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Axogen, Inc. director Kathy Johnson Weiler reported selling 14,150 shares of common stock on August 7, 2026 in a sale classified as an open market or private transaction. The weighted average sale price was $45.298 per share, with individual trades ranging from $44.43 to $46.47. Following this transaction, the reporting person held 0 shares directly. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026.

Insights

Analyzing...

Insider Trade Summary 10b5-1

Net Seller: 14,150 shares

Net Sell 1 txn

Insider Weiler Kathy Johnson

Role Director

Sold 14,150 shs ($641K)

Type	Security	Shares	Price	Value
Sale	Common Stock ^{F1, F2}	14,150	$45.298	$641K

Holdings After Transaction: Common Stock — 0 shares (Direct)

Footnotes (2)

F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2026.
F2. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $44.43 to $46.47 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 14,150 shares Weighted average sale price: $45.298 per share Sale price range: $44.43–$46.47 per share +2 more

5 metrics

Shares sold 14,150 shares Common stock sale by director on August 7, 2026

Weighted average sale price $45.298 per share Average price for the reported 14,150-share sale

Sale price range $44.43–$46.47 per share Range of prices across multiple sale transactions

Shares held after transaction 0 shares Directly owned Axogen common stock following the sale

10b5-1 plan adoption date May 8, 2026 Date the Rule 10b5-1 trading plan was adopted

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, open market or private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"sales reported were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The reported price in Column 4 is a weighted average sale price."

open market or private transaction financial

"transaction code description: Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Axogen, Inc. (AXGN) report in this Form 4?

Axogen, Inc. reported that director Kathy Johnson Weiler sold 14,150 shares of common stock on August 7, 2026. The transaction was classified as a sale in an open market or private transaction and left her with 0 directly held shares afterward.

At what prices were the Axogen (AXGN) shares sold by Kathy Johnson Weiler?

The reported weighted average sale price was $45.298 per share. According to the disclosure, the 14,150 shares were sold in multiple trades at prices ranging from $44.43 to $46.47 per share, with detailed trade breakdowns available on request.

Was the Axogen (AXGN) insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Kathy Johnson Weiler on May 8, 2026. Such pre-arranged plans allow insiders to execute trades according to predetermined instructions over time.

How many Axogen (AXGN) shares does Kathy Johnson Weiler hold after this reported sale?

After the reported sale of 14,150 shares, the Form 4 lists 0 shares of Axogen common stock held directly by Kathy Johnson Weiler. The report does not list any additional derivative positions or indirect holdings in this particular filing.

What role does the reporting person in this Axogen (AXGN) Form 4 hold at the company?

The reporting person, Kathy Johnson Weiler, is identified in the disclosure as a director of Axogen, Inc. She is not listed as an officer or 10% owner in this filing, which focuses on her reported common stock sale transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/11/2026 - 04:16 PM Accepted by SEC EDGAR 08/11/2026 - 04:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weiler Kathy Johnson

(Last)

(First)

(Middle)

C/O AXOGEN, INC. 13631 PROGRESS BLVD.,

SUITE 400

(Street)

ALACHUA

FLORIDA

32615

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Axogen, Inc. [ AXGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/07/2026		S⁽¹⁾		14,150	D	$45.298⁽²⁾	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2026.

2. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $44.43 to $46.47 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Marc Began, as attorney-in-fact for Kathy Weiler	08/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR